The thesis of this innovative and challenging book, first published in 2001, is that brain drug development has been restricted by the failure of adequate brain drug targeting, and that this is an increasingly urgent problem as developments in genomics lead to new generations of therapeutic macromolecules. The author, a world leader in the study of the blood-brain barrier and its clinical implications, reviews the field of neurotherapeutics from the point of view of drug targeting. He surveys the scientific and clinical basis of drug delivery across biological membranes, including topics such as genetically engineered trojan horses for drug targeting, antisense neurotherapeutics, and gene therapy of brain disorders. At a time when there are few significant new drug treatments in prospect for common neurological diseases, this authoritative review will encourage a wide range of clinicians and neuroscientists to reexamine the development and use of drugs in treating disorders of the central nervous system.

Review of the hardback:‘… a book that will become a standard on drug targeting to the brain … a must for everybody who works in the field of brain drug delivery in academia as well as in the pharmaceutical industry.’

W. Kamphorst - www.bmjbookshop.com

Review of the hardback:‘This book provides an extensive review of brain drug targeting of large molecules and will be a valuable reference to those interested in completing research in this field.’

Tejal Patel Source: Doody’s Health Sciences Book Review Journal

Review of the hardback:‘This is an excellent book to be expected from a major researcher in the field. The lucid text is illuminated by an eclectic mix of diagrams and plates that will have a broad appeal to a wide audience.’

A. Davenport Source: British Journal of Neurosurgery